EXPERIMENTAL AND CLINICAL EVALUATION OF CEFSULODIN IN THE FIELD OF PEDIATRIC INFECTION

• Published in: Japanese journal of antibiotics Vol. 35; no. 11; pp. 2657 - 2675
• Main Authors: TOYONAGA, YOSHIKIYO, SUGITA, MORIMASA, KUROSU, YOSHIIE, HORI, MAKOTO, HIROOKA, JUNKO, YOKOI, SHIGEO, KITANI, NOBUYUKI, TAKAHASHI, TAKAYUKI, NISHIYAMA, HIROTAKA
• Format: Journal Article
• Language: Japanese
• Published: Japan Japan Antibiotics Research Association 01.11.1982
• Subjects: Adolescent; Age Factors; Cefsulodin; Cephalosporins - metabolism; Cephalosporins - pharmacology; Cephalosporins - therapeutic use; Child; Child, Preschool; Clinical Trials as Topic; Drug Resistance, Microbial; Female; Humans; Male; Pseudomonas aeruginosa - drug effects; Pseudomonas Infections - drug therapy
• ISSN: 0368-2781; 2186-5477
• DOI: 10.11553/antibiotics1968b.35.2657

Experimental and clinical evaluation of cefsulodin (CFS), a newly developed injectable cephalosporin, was made and the following results were obtained. 1.Antimicrobial activity Antimicrobial activity of CFS against P.aeruginosa was studied with the inoculum size of 108 and 106 CFU/ml. In case of108CFU/ml inoculum size, MIC distributed in the range of6.25to50tug/mland peak distribution was between6.25μg/mland12.5μg/ml.Growth of 76% P.aeruginosa wasinhibited by12.5tug/mlconcentration. With106CFU/ml inoculum size, MIC range was1.56to 25μg/ml, peak distribution was3.13aug/mland80% inhibitory concentration was6.25μg/ml Irrespective of inoculum size, antimicrobial activity of CFS was1to2times superior to CPZ and PIPC, 4to 5times to CBPC and2times inferior to TOB. 2.Absorption and distribution Ten, 15, 20mg/kg and50mg/kg CFS was administered by one-shot intravenous injection and15, 50mg/kg CFS by intravenous drip infusion.The peak serum level was noticed after30minutes of injection (initial serum collection) in one-shot cases with the amount of 34.5, 31.1, 53.4μg/ml and89.3μ/ml respectively and, in dri infusion cases, at the end of infusion with46.8, 102.2μg/mlrespectively. Half life time were1.21, 1.31, 1.64, 1.08, 1.21 hours and 1.30 hours respectively. Urinary recovery rate until 6 hours from the start of injection in15, 20mg/kg and50mg/kg one-shot intravenous injection as well as15, 50mg/kg intravenous drip infusion cases were, 38.4-61.4, 51.7, 34.4-43.9, 37.0-40.0% and 35.8-74.3%respectively. 3.Clinical result CFS was administered to 5 cases of bronchopneumonia, 2 of septicemia, 2of UTI, 2 of postoperative wound infection, 1of epididymitis and 1 of peritonitis, i.e. total13 cases with P.aeruginosa infection. CFS was administered 65 to150mg/kg daily from 7 to 19 days and clinical result was excellent in1, good in 11 and poor in1case with the efficacy rate of92.3%. Ineffective case was septicemia in the terminal stage of leukemia accompanying ecthyma gangraenosum and posterior subperitoneal abscess. As for bacteriological effect, P.aeruginosa was eradicated in 9 out of 13 cases and eradication rate wa 69.2%. Side effect and abnormal change o laboratory findings to be caused by CFS administration have not been noticed. As the result of the study above mentioned, CFS is considered to be the useful drug for the treatment of the infection caused by P. aeruginosa in the pediatric field.